C4 Therapeutics, Inc. (CCCC)
- Previous Close
6.24 - Open
6.30 - Bid 6.13 x 1000
- Ask 6.17 x 1000
- Day's Range
6.12 - 6.37 - 52 Week Range
1.06 - 11.88 - Volume
1,046,912 - Avg. Volume
2,511,634 - Market Cap (intraday)
423.266M - Beta (5Y Monthly) 3.19
- PE Ratio (TTM)
-- - EPS (TTM)
-2.67 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.50
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
www.c4therapeutics.comRecent News: CCCC
Performance Overview: CCCC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CCCC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CCCC
Valuation Measures
Market Cap
423.27M
Enterprise Value
240.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.76
Price/Book (mrq)
1.72
Enterprise Value/Revenue
11.59
Enterprise Value/EBITDA
-1.88
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.53%
Return on Equity (ttm)
-49.50%
Revenue (ttm)
20.76M
Net Income Avi to Common (ttm)
-132.49M
Diluted EPS (ttm)
-2.67
Balance Sheet and Cash Flow
Total Cash (mrq)
253.68M
Total Debt/Equity (mrq)
28.84%
Levered Free Cash Flow (ttm)
-66.06M